COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 1 of 1 for:    NCT03439137
Previous Study | Return to List | Next Study

Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Currently Receiving ESAs With Anemia Associated With Chronic Kidney Disease in Japan

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03439137
Recruitment Status : Completed
First Posted : February 20, 2018
Last Update Posted : October 31, 2019
Information provided by (Responsible Party):
Mitsubishi Tanabe Pharma Corporation

Brief Summary:
For hemodialysis subjects currently receiving ESAs with anemia associated with chronic kidney disease, demonstrate non-inferiority of MT-6548 compared to darbepoetin alfa using Hb value and evaluate long-term safety of MT-6548.

Condition or disease Intervention/treatment Phase
Anemia; Hemodialysis Dependent Chronic Kidney Disease Drug: MT-6548 Drug: Darbepoetin alfa Drug: MT-6548-matching placebo Drug: Darbepoetin alfa-matching placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 323 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase III, Double Blind, Confirmatory Study of MT-6548 Compared to Darbepoetin Alfa in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan
Actual Study Start Date : February 14, 2018
Actual Primary Completion Date : December 12, 2018
Actual Study Completion Date : July 16, 2019

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: MT-6548 Drug: MT-6548
Oral tablet
Other Names:
  • vadadustat
  • AKB-6548

Drug: Darbepoetin alfa-matching placebo
Intravenous administration

Active Comparator: Darbepoetin alfa Drug: Darbepoetin alfa
Intravenous administration

Drug: MT-6548-matching placebo
Oral tablet

Primary Outcome Measures :
  1. Mean Hb level of Week 20 and Week 24 [ Time Frame: Up to Week 24 ]

Secondary Outcome Measures :
  1. Mean Hb level of Week 48 and Week 52 [ Time Frame: Up to Week 52 ]
  2. Hb level at each assessment time point [ Time Frame: Up to Week 52 ]
  3. Proportion of subjects with Hb level at each assesment time point within the target range [ Time Frame: Up to Week 52 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of CKD
  • Receiving hemodialysis or hemodiafiltration 3 times a week for more than 12 weeks prior to the screening period, excluding receiving home dialysis or combination of peritoneal dialysis.
  • Being treated with ESAs for the recent 8 weeks prior to the screening period
  • Mean of the two screening Hb levels closest in time to the baseline visit is ≥9.5 g/dL and ≤12.0 g/dL
  • Fluctuation between the two Hb levels closest in time to the baseline visit during the screening period less than 1.5 g/dL
  • Serum ferritin ≥ 100 ng/mL, or TSAT ≥20% during the screening period
  • Folate and vitamin B12 ≥ lower limit of normal during the screening period

Exclusion Criteria:

  • Anemia due to a main cause other than CKD: sickle cell disease, myelodysplastic syndrome, bone marrow fibrosis, hematologic malignancy, hemolytic anemia, thalassemia, or pure red cell aplasia
  • Active bleeding or recent blood loss within 8 weeks prior to the screening period
  • RBC transfusion within 8 weeks prior to the screening period
  • Received testosterone enanthate or mepitiostane within 8 weeks prior to the screening period
  • AST, ALT, or total bilirubin >2.5 x upper limit of normal during the screening period
  • Uncontrolled hypertension (diastolic blood pressure >110 mm Hg or systolic blood pressure >180 mm Hg) at the first day of the screening period and Day 1
  • Ophthalmic examinations during the screening period correspond to either of the following criteria;

    • No available fundal findings
    • Findings indicating the presence of active fundal disease
  • Severe heart failure (New York Heart Association Class IV)
  • Cerebrovascular disorder or acute coronary syndrome (hospitalization due to unstable angina or myocardial infarction), requiring hospitalization due to urgent percutaneous intervention for coronary or heart failure within 12 weeks prior to the screening period
  • Current or history of malignancy. History of malignancy with no recurrence for the recent 5 years is not an exclusion criterion
  • New onset or recurrent event of deep vein thrombosis or pulmonary embolism within 12 weeks prior to the screening period
  • Current or history of hemosiderosis or hemochromatosis
  • History of prior organ transplantation or scheduled organ transplant, or prior transplantation of hematopoietic stem cell or bone marrow
  • Males and females of childbearing potential who are unwilling to use an acceptable method of contraception during the designated period (Males: during the study and 90 days after the last dose, females: during study and 30 days after the last dose)
  • Females who are pregnant or breast feeding, or are predicted to be pregnant

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03439137

Layout table for location information
Research site
Aichi, Japan
Research site
Chiba, Japan
Research site
Fukui, Japan
Research site
Fukuoka, Japan
Research site
Fukushima, Japan
Research site
Gunma, Japan
Research site
Hiroshima, Japan
Research site
Hokkaido, Japan
Research site
Hyogo, Japan
Research site
Ibaraki, Japan
Research site
Kagawa, Japan
Research site
Kagoshima, Japan
Research site
Kanagawa, Japan
Research site
Kumamoto, Japan
Research site
Kyoto, Japan
Research site
Miyagi, Japan
Research site
Nagano, Japan
Research site
Nagasaki, Japan
Research site
Oita, Japan
Research site
Okayama, Japan
Research site
Okinawa, Japan
Research site
Osaka, Japan
Research site
Saitama, Japan
Research site
Shiga, Japan
Research site
Shizuoka, Japan
Research site
Tokushma, Japan
Research site
Tokyo, Japan
Research site
Yamagata, Japan
Sponsors and Collaborators
Mitsubishi Tanabe Pharma Corporation
Layout table for investigator information
Study Director: General Manager Mitsubishi Tanabe Pharma Corporation
Layout table for additonal information
Responsible Party: Mitsubishi Tanabe Pharma Corporation Identifier: NCT03439137    
Other Study ID Numbers: MT-6548-J03
First Posted: February 20, 2018    Key Record Dates
Last Update Posted: October 31, 2019
Last Verified: October 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Kidney Diseases
Renal Insufficiency, Chronic
Hematologic Diseases
Urologic Diseases
Renal Insufficiency
Darbepoetin alfa